NeonMind Announces New Specialty Clinics Division to Deliver Innovative Mental Health Services, Appoints New VP, Corporate Development
4/21/2021
1/3
NeonMind Announces New Specialty Clinics Division to Deliver Innovative Mental Health
Services, Appoints New VP, Corporate Development
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2021) - NeonMind Biosciences Inc. (CSE:
NEON) (OTC PINK: NMDBF) (FFE: 6UF) ("NeonMind"), a psychedelic drug development company, is
pleased to announce that it is establishing a medical services division for the delivery of evidence-backed
innovative treatments for a variety of mental health needs. This will include psychedelic modalities and other
newer treatments for mood disorders such as depression.
Figure 1: NeonMind Announces New Specialty Clinics Division to Deliver Innovative Mental Health Services,
Appoints New VP, Corporate Development
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/7646/81354_neonmi2.jpg
NeonMind is assembling a team of experts to plan and launch a chain of NeonMind-branded clinics in Canada.
Working with health care communities and tailoring the services to local market needs, these clinics will offer
various treatments for mental health, including psychedelic therapeutics and drug-enhanced psychotherapy.
"Our vision is to build an integrated services platform and comprehensive set of programs aimed at delivering
specialized treatments combined with traditional modalities for a variety of mental health conditions and right-
sized for local needs," said Robert Tessarolo, President and CEO of NeonMind. "A major impetus for this
strategic decision is that psychedelic drugs used to enhance psychotherapy are set to be a game-changing
treatment tool, and infrastructure development is needed to provide access points for these innovative
treatments."
In Canada, ketamine and esketamine are currently the only psychedelic substances that may legally be prescribed
and administered in medical clinics, but there is a large and growing pipeline of psychedelic drug development
programs with clinical trials underway evaluating other substances including psilocybin. Importantly recent
clinical trial results with psilocybin treatment are showing promise.
4/21/2021
2/3
The platform will be designed to expand to increase offerings of drug-enhanced psychotherapies over time.
NeonMind aims to gain an early-mover advantage, establish a strategic footprint, and have operations ready to
accommodate a future surge from potential psychedelic drug approvals.
"We believe that there are gaps that have not yet been filled for localized services and underserved markets, and
will begin laying our foundations now with specialty mental health services, and then evolve our clinic model
over time with changing market needs and with the availability of new drug-enhanced psychotherapies," added
Rob Tessarolo.
NeonMind has appointed Ernie Ho as VP, Corporate Development, with his initial focus to be the development
of the team to build out medical services as well as to identify and assess partnership and acquisition targets.
Ernie's background spans both biopharma and healthcare services, with experience in product development,
commercialization, and corporate development. At LifeLabs, Canada's largest medical diagnostics provider, he
developed and successfully launched innovative medical services with a focus on client needs and improved
outcomes including point-of-care testing and mobile testing services.
"Ernie also has extensive experience in biopharma including playing pivotal roles in licensing and M&A at
Cipher Pharmaceuticals, and raising capital to support product development at Therapure Biopharma (now part
of Resilience Biotechnologies). These skill sets are highly complementary to our company strategy," added Rob
Tessarolo.
Now more than ever,mental illness is having a devastating impact on society and access to treatments remains an
issue. The devastation of the COVID-19 pandemic - millions of deaths, economic hardship and unprecedented
restrictions on social interaction - has already had a marked effect on people's mental health. According to a
Kaiser Family Foundation health tracking poll, more than 40% of people in the U.S. reported deteriorating
mental health including symptoms of anxiety disorder or depressive disorder due to COVID-19, representing 2 -
4 times the number affected people before COVID. 38% of participants in a Matchbox survey in Canada
reported a decline in mental health due to COVID-19.
About NeonMind Biosciences Inc.
NeonMind is engaged in research and development of products to optimize human health and performance.
NeonMind has two divisions, a pharmaceutical division engaged in drug development of psychedelic
compounds, and a consumer products division with a focus on mushroom infused products. NeonMind's
consumer division currently sells NeonMind branded coffee products in Canada through NeonMind's direct to
consumer e-commerce platform, and it has plans to launch dietary supplements in the United States this spring.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting
obesity. NeonMind's first drug candidate aims to use synthetic psilocybin to enhance a patient's ability to adopt
behaviours that cause weight loss and maintain that loss through psychedelic-assisted cognitive therapy. The
second drug candidate offers low dose synthetic psilocybin as a treatment to suppress appetite.
NeonMind's first drug candidate employs psilocybin as an agonist to the serotonin receptor 5- HT2A, which is
involved in the hallucinogenic effect of psychedelics, and the second drug candidate employs low-dose
psilocybin as an agonist to the 5-HT2C receptor, which controls appetite.
For more information on NeonMind, go to www.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
Tel: 416-750-3101
Investor Relations:
Edge Communications
4/21/2021
3/3
Tel: 1-866-318-6874
Renmark Financial Communications Inc.
Melanie Barbeau
mbarbeau@renmarkfinancial.com
Tel: 416-644-2020 or 212-812-7680
Media Inquiries:
Exvera Communications Inc.
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news
release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements
relate to future events or NeonMind's future performance. The use of any of the words "could", "expect",
"believe", "will", "projected","estimated" and similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information and are based on NeonMind's current belief
or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In
particular, NeonMind's drug development plans, its ability to retain key personnel, and its expectation as to the
development of its intellectual property and other steps in its preclinical and clinical drug development
constitute forward-looking information. Actual results and developments may differ materially from those
contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-
looking information. The statements made in this press release are made as of the date hereof. NeonMind
disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as may be expressly required by applicable
securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/81354